Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. The agency is now heavily scrutinizing Phase 1 and 2 studies to see whether they identify the safest and most effective dose—while this change seems abrupt, it’s loomed over the field for a long time.
We’ve helped our clients adapt to the new standards with five best practices outlined in this article.
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Blog
UK's nonclinical roadmap: MHRA joins global regulatory shift toward NAMs with detailed goals and timelines
Jan 8, 2026
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
New Oncology head brings biotech industry and academic research experience
Oct 2, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Blog
UK's nonclinical roadmap: MHRA joins global regulatory shift toward NAMs with detailed goals and timelines
Jan 8, 2026
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
New Oncology head brings biotech industry and academic research experience
Oct 2, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023